host-directed therapeutics

AuraVax Therapeutics, Inc. is commercializing its intranasal platform called NanoSTING to treat and prevent respiratory infections independent of the pathogen. NanoSTING technology activates the STING pathway to restore and boost innate immunity. The company is developing its technology as a new class of host-directed-therapeutics to treat infections from respiratory pathogens, and is also pursuing NanoSTING to improve intranasal vaccines.

Read more

intranasal drug developmentvaccine adjuvant development

CMTx Biotech, Inc. is a Stony Brook, NY company developing medical countermeasures against high priority CBRN threats. It pursues drug rescue and repositioning, including new therapeutic uses and formulations of clinical stage drug candidates and of drugs already approved for human use. Its science focuses on host-directed therapeutics (HDTs) targeting hyper-inflammatory and dysregulated immune responses to infection, insult, or injury. Lead candidate incyclinide has completed IND-enabling studies; CMTx R2 is an STS protein inhibitor advanced for host-di

Read more

drug developmentdrug repurposingIND-enabling studiesmanufacturingtechnology commercialization and licensing